# A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities

> **NCT03713658** · PHASE4 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 34 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Risperidone 3 mg
- **DRUG:** Paliperidone Palmitate 50 mg eq.
- **DRUG:** Paliperidone Palmitate 75 mg eq.
- **DRUG:** Paliperidone Palmitate 100 mg eq.
- **DRUG:** Paliperidone Palmitate 150 mg eq.
- **DRUG:** Paliperidone Palmitate 175 mg eq.
- **DRUG:** Paliperidone Palmitate 263 mg eq.
- **DRUG:** Paliperidone Palmitate 350 mg eq.
- **DRUG:** Paliperidone Palmitate 525 mg eq.

## Key facts

- **NCT ID:** NCT03713658
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-18
- **Primary completion:** 2019-12-02
- **Final completion:** 2019-12-02
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03713658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03713658, "A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT03713658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*